Literature DB >> 3164530

Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).

K Andrassy1, K Mörike, J Koderisch, E Weber.   

Abstract

The effect of a low molecular weight heparin (Fragmin) (20-80 U/kg) was studied in 10 healthy male volunteers after intravenous administration. Clotting abnormalities are extensive shortly after injection, lasting for 1-2 hours depending on heparin dosage. Dilute thrombin time, showing a close correlation to anti-F-Xa activity, is as sensitive as anti-F-Xa. The parallel time course of dilute thrombin time and anti-F-Xa activity clearly demonstrates that LMWH has an effect on F-IIa lasting as long as that of F-Xa. After subcutaneous administration clotting abnormalities are only slight with 40-60 U/kg, in contrast to the intravenous study. The platelet system remains unchanged.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164530     DOI: 10.1016/0049-3848(88)90257-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  The possible involvement of platelet activation in endotoxin-induced renal insufficiency in a rabbit model.

Authors:  M Yokota; J Kambayashi; M Sakon; H Tahara; E Shiba; T Kawasaki; T Mori
Journal:  Jpn J Surg       Date:  1991-09

2.  Delivery of low molecular weight heparin for prophylaxis against deep vein thrombosis using a novel, needle-less injection device (J-Tip).

Authors:  S J Hollingsworth; K Hoque; D Linnard; D G Corry; S G Barker
Journal:  Ann R Coll Surg Engl       Date:  2000-11       Impact factor: 1.891

Review 3.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.